Please telephone us on 01276 698691 or email us via the link below with all media enquiries .

Please note that this service handles press enquiries from journalists only. 
If you require information or advice about your medication or treatment please contact your healthcare professional.
More information about our products can be found by following the links to the appropriate business area.

Press releases listed on this page were issued in the United Kingdom and are intended for reference information. The information contained in each press release was accurate at the time of issuance, and Novartis Pharmaceuticals UK Limited assumes no responsibility for updating the information to reflect subsequent developments.

Novartis UK will continue to supply pharmaceuticals into community via wholesale using simplified distribution network.

New licence for Cubicin® (daptomycin), the first in a novel class of antibiotic, is announced today for the treatment of serious bloodstream and heart infections caused by the most problematic UK organisms, including MRSA

First product in a new class of medicine to treat high blood pressure in over 10 years now available in the UK

Clinicians welcome NICE decision to grant NHS patients access to Xolair® (omalizumab) - a first-in-class treatment for severe, persistent allergic asthma